Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.

Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.

Compositions, methods, and kits for treating dry eye and related diseases are provided. In one aspect, the present disclosure relates to administering thermoresponsive polymeric compositions to the tear duct of the subject. Administering a thermoresponsive polymeric composition to the tear duct of the subject may be useful in treating dry eye and related conditions.

Compositions, methods, and kits for treating dry eye and related diseases are provided. In one aspect, the present disclosure relates to administering thermoresponsive polymeric compositions to the tear duct of the subject. Administering a thermoresponsive polymeric composition to the tear duct of the subject may be useful in treating dry eye and related conditions.

In one aspect, provided is an aqueous antiseptic composition comprising glycerin 8.5-16% by weight; caprylyl glycol 0.45-3% by weight; and a first ingredient; wherein the first ingredient is acrylates/C10-30 about 0.01-0.1% by weight or ethoxydiglycol about 1-5% by weight. The glycerin, the caprylyl glycol and the first ingredient taken together form a first component. A sum of the first component is more than 13% by weight of the antiseptic composition. Other exemplary embodiments are also described. In certain embodiments, provided is an antiseptic composition useful for making skin or hand sanitizers that have a long-lasting, great antiseptic efficacy but at the same time having skin-moisturizing, low toxicity and low skin-irritating, hypo-allergenic properties, low inflammability, and low production cost.

In one aspect, provided is an aqueous antiseptic composition comprising glycerin 8.5-16% by weight; caprylyl glycol 0.45-3% by weight; and a first ingredient; wherein the first ingredient is acrylates/C10-30 about 0.01-0.1% by weight or ethoxydiglycol about 1-5% by weight. The glycerin, the caprylyl glycol and the first ingredient taken together form a first component. A sum of the first component is more than 13% by weight of the antiseptic composition. Other exemplary embodiments are also described. In certain embodiments, provided is an antiseptic composition useful for making skin or hand sanitizers that have a long-lasting, great antiseptic efficacy but at the same time having skin-moisturizing, low toxicity and low skin-irritating, hypo-allergenic properties, low inflammability, and low production cost.

An injectable medical composition includes an acrylate and a solvent. The composition has a first viscosity at temperatures below body temperature and a second viscosity at body temperature. The first viscosity is lower than the second viscosity.

The present disclosure generally relates to the field of infertility, and in particular female infertility. Accordingly, the present disclosure provides for compositions and methods for managing female infertility, caused by Asherman's syndrome. More particularly, the present disclosure provides a therapeutic composition comprising a platelet-derived growth factor concentrate and a thermoresponsive polymer. The present disclosure also relates to the PRP and the concentrate themselves. Consequently, methods to obtain said compositions, along with therapeutic applications for treatment of Asherman's syndrome are also provided.

Disclosed herein are fully synthetic polymer-based lung surfactant materials, for the first time, as next generation SRT. In vitro studies on these polymer lung surfactants show that the candidate materials effectively mimic the surface tension controlling properties of currently marketed natural lung surfactants. Further, the polymer lung surfactants have strong protein resistance, which makes this class of materials promising also for potential use in Acute Respiratory Distress Syndrome (ARDS) treatment.

Disclosed herein are fully synthetic polymer-based lung surfactant materials, for the first time, as next generation SRT. In vitro studies on these polymer lung surfactants show that the candidate materials effectively mimic the surface tension controlling properties of currently marketed natural lung surfactants. Further, the polymer lung surfactants have strong protein resistance, which makes this class of materials promising also for potential use in Acute Respiratory Distress Syndrome (ARDS) treatment.